SynthesiseLife2021
Sensitivity of ID NOW and RT-PCR for detection of SARS-CoV-2 in an ambulatory population.
Synthesis in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Pooled it
- Intensified screening for SARS-CoV-2 in 18 emergency departments in the Paris metropolitan area, France (DEPIST-COVID): A cluster-randomized, two-period, crossover trial.PLoS medicine · 2023Trial
- A comparative study of COVID-19 point-of-care detection across human biofluids using MEMS-based near-infrared spectroscopy and machine learning.Biomedical microdevices · 2026Article
- Peptide Probe-Based NanoLC-MS/MS PRM for Ultrasensitive Detection of SARS-CoV-2 Proteins in Environmental Samples.Infectious diseases & clinical microbiology · 2026Article
- [Implementation of isotermic PCR for detection of SARS-CoV-2 virus].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- Improvement of Sensitivity and Speed of Virus Sensing Technologies Using nm- and μm-Scale Components.Sensors (Basel, Switzerland) · 2023Review
- Detection of SARS-CoV-2 Based on Nucleic Acid Amplification Tests (NAATs) and Its Integration into Nanomedicine and Microfluidic Devices as Point-of-Care Testing (POCT).International journal of molecular sciences · 2023Review
- COVID-19 Antigen Results Correlate with the Quantity of Replication-Competent SARS-CoV-2 in a Cross-Sectional Study of Ambulatory Adults during the Delta Wave.Microbiology spectrum · 2023Article
- Point-of-Care Testing for SARS-CoV-2: A Prospective Study in a Primary Health Centre.Diagnostics (Basel, Switzerland) · 2023Article
- An analysis of emergency surgery on coronavirus disease positive patients and their outcomes during the coronavirus pandemic: A retrospective observational study.Medical journal, Armed Forces India · 2023Article
- COVID-19 rapid molecular point-of-care testing is effective and cost-beneficial for the acute care of trauma patients.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2023Article
- Article
- Cas12a-assisted RTF-EXPAR for accurate, rapid and simple detection of SARS-CoV-2 RNA.Biosensors & bioelectronics · 2022Article
- Miniaturized Real-Time PCR systems for SARS-CoV-2 detection at the Point-of-Care.Clinica chimica acta; international journal of clinical chemistry · 2022Review
- A complete blood count-based multivariate model for predicting the recovery of patients with moderate COVID-19: a retrospective study.Scientific reports · 2022Article
- FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances.Biosensors & bioelectronics: X · 2022Review
- Toward smart diagnosis of pandemic infectious diseases using wastewater-based epidemiology.Trends in analytical chemistry : TRAC · 2022Review
- Clinical Diagnostic Point-of-Care Molecular Assays for SARS-CoV-2.Clinics in laboratory medicine · 2022Review
- Comparison of Abbott ID NOW, a novel isothermal amplification based COVID-19 diagnostic method with RTPCR.Journal of virological methods · 2022Article
- Diagnostic accuracy of the Abbott ID NOW SARS-CoV-2 rapid test for the triage of acute medical admissions.The Journal of hospital infection · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Diagnosis of SARS-CoV-2 (COVID-19) requires confirmation by reverse transcription-polymerase chain reaction (RT-PCR). Abbott ID NOW provides fast results but has been criticized for low sensitivity. Here we determine the sensitivity of ID NOW in an ambulatory population presented for testing. The study enrolled 785 symptomatic patients, of whom 21 were positive by both ID NOW and RT-PCR, and 2 only by RT-PCR. All 189 asymptomatic patients tested negative. The positive percent agreement between the ID NOW assay and the RT-PCR assay was 91.3%, and negative percent agreement was 100%. The results from the current study were included into a larger systematic review of literature where at least 20 subjects were simultaneously tested using ID NOW and RT-PCR. The overall sensitivity for ID NOW assay was calculated at 84% (95% confidence interval 55-96%) and had the highest correlation to RT-PCR at viral loads most likely to be associated with transmissible infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.